180 related articles for article (PubMed ID: 20102634)
1. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.
Christodoulopoulos I; Droniou-Bonzom ME; Oldenburg JE; Cannon PM
Retrovirology; 2010 Jan; 7():4. PubMed ID: 20102634
[TBL] [Abstract][Full Text] [Related]
2. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
3. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu.
Lucas TM; Lyddon TD; Cannon PM; Johnson MC
J Virol; 2010 Mar; 84(6):2666-74. PubMed ID: 20042505
[TBL] [Abstract][Full Text] [Related]
4. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
Lucas TM; Janaka SK; Stephens EB; Johnson MC
PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
[TBL] [Abstract][Full Text] [Related]
5. Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu.
Janaka SK; Lucas TM; Johnson MC
J Virol; 2011 Nov; 85(22):11945-54. PubMed ID: 21917962
[TBL] [Abstract][Full Text] [Related]
6. Functional complementation of a model target to study Vpu sensitivity.
Janaka SK; Faurot J; Johnson MC
PLoS One; 2013; 8(6):e68507. PubMed ID: 23840857
[TBL] [Abstract][Full Text] [Related]
7. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
8. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
Mitchell RS; Katsura C; Skasko MA; Fitzpatrick K; Lau D; Ruiz A; Stephens EB; Margottin-Goguet F; Benarous R; Guatelli JC
PLoS Pathog; 2009 May; 5(5):e1000450. PubMed ID: 19478868
[TBL] [Abstract][Full Text] [Related]
9. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
10. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1.
Stitz J; Buchholz CJ; Engelstädter M; Uckert W; Bloemer U; Schmitt I; Cichutek K
Virology; 2000 Jul; 273(1):16-20. PubMed ID: 10891403
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.
Gustin JK; Douglas JL; Bai Y; Moses AV
J Biol Chem; 2012 Apr; 287(18):14837-50. PubMed ID: 22383521
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins.
Ramirez PW; DePaula-Silva AB; Szaniawski M; Barker E; Bosque A; Planelles V
Retrovirology; 2015 Jul; 12():65. PubMed ID: 26215564
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of β-TrcP-dependent ubiquitination of p53 by HIV-1 Vpu promotes p53-mediated apoptosis in human T cells.
Verma S; Ali A; Arora S; Banerjea AC
Blood; 2011 Jun; 117(24):6600-7. PubMed ID: 21521785
[TBL] [Abstract][Full Text] [Related]
14. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors.
Christodoulopoulos I; Cannon PM
J Virol; 2001 May; 75(9):4129-38. PubMed ID: 11287562
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
[TBL] [Abstract][Full Text] [Related]
17. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu.
Tokarev AA; Munguia J; Guatelli JC
J Virol; 2011 Jan; 85(1):51-63. PubMed ID: 20980512
[TBL] [Abstract][Full Text] [Related]
18. Novel Compound Inhibitors of HIV-1
Robinson CA; Lyddon TD; Gil HM; Evans DT; Kuzmichev YV; Richard J; Finzi A; Welbourn S; Rasmussen L; Nebane NM; Gupta VV; Ananthan S; Cai Z; Wonderlich ER; Augelli-Szafran CE; Bostwick R; Ptak RG; Schader SM; Johnson MC
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458546
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.
Hauser H; Lopez LA; Yang SJ; Oldenburg JE; Exline CM; Guatelli JC; Cannon PM
Retrovirology; 2010 Jun; 7():51. PubMed ID: 20529266
[TBL] [Abstract][Full Text] [Related]
20. β-TrCP dependency of HIV-1 Vpu-induced downregulation of CD4 and BST-2/tetherin.
Blanchet FP; Mitchell JP; Piguet V
Curr HIV Res; 2012 Jun; 10(4):307-14. PubMed ID: 22524179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
